Ardelyx Posts 73% Ibsrela Growth, Launches Phase 3, Sees $1B Peak Sales
Ardelyx reported 2025 product revenue with Ibsrela sales rising 73% year over year and maintained broad patient access to Xphozah. The company initiated a Phase 3 trial for Ibsrela in chronic idiopathic constipation, began development of next-generation NHE3 inhibitor RDX10531 and forecasts Ibsrela peak sales above $1 billion.
1. Revenue Performance
Ardelyx released preliminary, unaudited product revenue for Q4 and full-year 2025, reporting Ibsrela sales soared 73% year over year and Xphozah utilization remained stable across its patient base.
2. Pipeline Advancements
The company initiated a pivotal Phase 3 program evaluating Ibsrela in chronic idiopathic constipation and advanced early-stage research on its next-generation NHE3 inhibitor candidate, RDX10531.
3. Outlook and Guidance
Entering 2026, Ardelyx forecasts Ibsrela peak sales exceeding $1 billion, underpinned by patent protection to 2041, and highlighted its strong cash position to fuel ongoing commercialization and pipeline development.